Drug Trial Radar · NCT00982007
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
Last checked: Nov 19, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
997
Actual
Start
Sep 2009
Primary completion
Mar 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- American Regent, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to demonstrate the efficacy and safety of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to oral iron in subjects who have iron deficiency anemia (IDA) and have shown an unsatisfactory response to oral iron.
Conditions
- Iron Deficiency Anemia
Interventions
Ferric Carboxymaltose (FCM)Drug
A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
Ferrous Sulfate TabletsDrug
325 mg Ferrous Sulfate tablets taken orally three times a day
IV Iron (standard of care)Drug
IV standard of care (other IV iron) per the Investigator's discretion
Ferric Carboxymaltose (FCM)Drug
A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.Time frame: Day 35
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Luitpold Pharmaceuticals, Inc.
Norristown, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.